Previous Close | 2.1000 |
Open | 2.0500 |
Bid | 1.0000 x 1000 |
Ask | 3.0000 x 1100 |
Day's Range | 2.0000 - 2.1900 |
52 Week Range | 1.9000 - 4.8300 |
Volume | |
Avg. Volume | 42,504 |
Market Cap | 96.252M |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CHESTER, N.Y., May 04, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022.
CHESTER, N.Y., May 02, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and c
CHESTER, N.Y., April 20, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report first quarter 2022 financial results on Wednesday, May 4, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corp